Advanced Enzyme Technologies Limited (ADVENZYMES) - Total Assets
Based on the latest financial reports, Advanced Enzyme Technologies Limited (ADVENZYMES) holds total assets worth Rs16.92 Billion INR (≈ $182.97 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Advanced Enzyme Technologies Limited's book value for net asset value and shareholders' equity analysis.
Advanced Enzyme Technologies Limited - Total Assets Trend (2008–2025)
This chart illustrates how Advanced Enzyme Technologies Limited's total assets have evolved over time, based on quarterly financial data.
Advanced Enzyme Technologies Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Advanced Enzyme Technologies Limited's total assets of Rs16.92 Billion consist of 54.3% current assets and 45.7% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs667.50 Million | 6.6% |
| Accounts Receivable | Rs1.16 Billion | 7.2% |
| Inventory | Rs1.57 Billion | 9.7% |
| Property, Plant & Equipment | Rs3.15 Billion | 19.4% |
| Intangible Assets | Rs523.08 Million | 3.2% |
| Goodwill | Rs3.33 Billion | 20.6% |
Asset Composition Trend (2008–2025)
This chart illustrates how Advanced Enzyme Technologies Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Advanced Enzyme Technologies Limited market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Advanced Enzyme Technologies Limited's current assets represent 54.3% of total assets in 2025, an increase from 40.4% in 2008.
- Cash Position: Cash and equivalents constituted 6.6% of total assets in 2025, up from 0.5% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is goodwill at 20.6% of total assets.
Advanced Enzyme Technologies Limited Competitors by Total Assets
Key competitors of Advanced Enzyme Technologies Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AKZO NOBEL SPONS.ADRS 1/3
F:AKUP
|
Germany | €13.95 Billion |
|
Air Products and Chemicals Inc
NYSE:APD
|
USA | $41.24 Billion |
|
Akzo Nobel NV
AS:AKZA
|
Netherlands | €13.95 Billion |
|
Swancor Advanced Materials Co Ltd
SHG:688585
|
China | CN¥2.24 Billion |
|
Azelis Group NV
BR:AZE
|
Belgium | €5.41 Billion |
|
Shenzhen Rongda Photosensitive & Technology Co Ltd
SHE:300576
|
China | CN¥2.07 Billion |
|
Jihua Group Corp Ltd
SHG:601718
|
China | CN¥20.16 Billion |
|
Jiangxi Guotai Civilian
SHG:603977
|
China | CN¥6.21 Billion |
Advanced Enzyme Technologies Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.75 | 7.75 | 7.27 |
| Quick Ratio | 7.12 | 6.13 | 5.81 |
| Cash Ratio | 0.72 | 1.07 | 0.00 |
| Working Capital | Rs8.27 Billion | Rs7.01 Billion | Rs3.84 Billion |
Advanced Enzyme Technologies Limited - Advanced Valuation Insights
This section examines the relationship between Advanced Enzyme Technologies Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.05 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 5.6% |
| Total Assets | Rs16.21 Billion |
| Market Capitalization | $420.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values Advanced Enzyme Technologies Limited's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Advanced Enzyme Technologies Limited's assets grew by 5.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Advanced Enzyme Technologies Limited (2008–2025)
The table below shows the annual total assets of Advanced Enzyme Technologies Limited from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs16.21 Billion ≈ $175.34 Million |
+5.59% |
| 2024-03-31 | Rs15.35 Billion ≈ $166.05 Million |
+7.99% |
| 2023-03-31 | Rs14.22 Billion ≈ $153.77 Million |
+12.17% |
| 2022-03-31 | Rs12.68 Billion ≈ $137.09 Million |
+9.97% |
| 2021-03-31 | Rs11.53 Billion ≈ $124.66 Million |
+17.79% |
| 2020-03-31 | Rs9.79 Billion ≈ $105.83 Million |
+20.65% |
| 2019-03-31 | Rs8.11 Billion ≈ $87.72 Million |
+10.86% |
| 2018-03-31 | Rs7.32 Billion ≈ $79.12 Million |
+26.90% |
| 2017-03-31 | Rs5.77 Billion ≈ $62.35 Million |
+27.98% |
| 2016-03-31 | Rs4.51 Billion ≈ $48.72 Million |
+8.32% |
| 2015-03-31 | Rs4.16 Billion ≈ $44.98 Million |
+2.42% |
| 2014-03-31 | Rs4.06 Billion ≈ $43.92 Million |
+2.54% |
| 2013-03-31 | Rs3.96 Billion ≈ $42.83 Million |
+13.36% |
| 2012-03-31 | Rs3.49 Billion ≈ $37.78 Million |
+126.89% |
| 2011-03-31 | Rs1.54 Billion ≈ $16.65 Million |
+41.17% |
| 2010-03-31 | Rs1.09 Billion ≈ $11.80 Million |
+15.98% |
| 2009-03-31 | Rs940.41 Million ≈ $10.17 Million |
+3.74% |
| 2008-03-31 | Rs906.55 Million ≈ $9.80 Million |
-- |
About Advanced Enzyme Technologies Limited
Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers enzymes and probiotics-based nutritional supplements for human healthcare and nutrition, animal nutrition, fruit and vegetable processing, baking, brewing … Read more